Aytu BioPharma, Inc. received U.S. Food & Drug Administration (FDA) approval of the Adzenys XR-ODT® (Adzenys) Prior Approval Supplement (PAS). This approval enables the transfer of manufacturing of Adzenys to the Company's third-party manufacturer.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.125 USD | +2.12% | +8.02% | +10.04% |
Feb. 14 | Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024 | |
Feb. 14 | Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.04% | 17.04M | |
+33.13% | 700B | |
-4.93% | 358B | |
+18.95% | 330B | |
+3.49% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+6.15% | 161B | |
-1.86% | 157B |
- Stock Market
- Equities
- AYTU Stock
- News Aytu BioPharma, Inc.
- Aytu BioPharma, Inc. Receives U.S. Food & Drug Administration Approval of the Adzenys XR-ODT Manufacturing of Adzenys to the Third-Party Manufacturer